Cargando…

Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial

BACKGROUND: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adul...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Akira, Yamakawa, Kazuma, Tagami, Takashi, Umemura, Yutaka, Takahashi, Kyosuke, Nagasawa, Hiroki, Araki, Yuichi, Kojima, Mitsuaki, Sera, Toshiki, Yagi, Masayuki, Yamamoto, Ryo, Takahashi, Jiro, Nakane, Masaki, Takeda, Chikashi, Narita, Chihiro, Kazuma, Satoshi, Okura, Hiroko, Takahashi, Hiroyuki, Wada, Takeshi, Tahara, Shu, Matsuoka, Ayaka, Masaki, Todani, Shiraishi, Atsushi, Shimoyama, Keiichiro, Yokokawa, Yuta, Nakamura, Rintaro, Sageshima, Hisako, Yanagida, Yuichiro, Takahashi, Kunihiko, Otomo, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509562/
https://www.ncbi.nlm.nih.gov/pubmed/36153530
http://dx.doi.org/10.1186/s13063-022-06732-9
_version_ 1784797251782049792
author Endo, Akira
Yamakawa, Kazuma
Tagami, Takashi
Umemura, Yutaka
Takahashi, Kyosuke
Nagasawa, Hiroki
Araki, Yuichi
Kojima, Mitsuaki
Sera, Toshiki
Yagi, Masayuki
Yamamoto, Ryo
Takahashi, Jiro
Nakane, Masaki
Takeda, Chikashi
Narita, Chihiro
Kazuma, Satoshi
Okura, Hiroko
Takahashi, Hiroyuki
Wada, Takeshi
Tahara, Shu
Matsuoka, Ayaka
Masaki, Todani
Shiraishi, Atsushi
Shimoyama, Keiichiro
Yokokawa, Yuta
Nakamura, Rintaro
Sageshima, Hisako
Yanagida, Yuichiro
Takahashi, Kunihiko
Otomo, Yasuhiro
author_facet Endo, Akira
Yamakawa, Kazuma
Tagami, Takashi
Umemura, Yutaka
Takahashi, Kyosuke
Nagasawa, Hiroki
Araki, Yuichi
Kojima, Mitsuaki
Sera, Toshiki
Yagi, Masayuki
Yamamoto, Ryo
Takahashi, Jiro
Nakane, Masaki
Takeda, Chikashi
Narita, Chihiro
Kazuma, Satoshi
Okura, Hiroko
Takahashi, Hiroyuki
Wada, Takeshi
Tahara, Shu
Matsuoka, Ayaka
Masaki, Todani
Shiraishi, Atsushi
Shimoyama, Keiichiro
Yokokawa, Yuta
Nakamura, Rintaro
Sageshima, Hisako
Yanagida, Yuichiro
Takahashi, Kunihiko
Otomo, Yasuhiro
author_sort Endo, Akira
collection PubMed
description BACKGROUND: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. METHODS: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. DISCUSSION: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. TRIAL REGISTRATION: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06732-9.
format Online
Article
Text
id pubmed-9509562
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95095622022-09-26 Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial Endo, Akira Yamakawa, Kazuma Tagami, Takashi Umemura, Yutaka Takahashi, Kyosuke Nagasawa, Hiroki Araki, Yuichi Kojima, Mitsuaki Sera, Toshiki Yagi, Masayuki Yamamoto, Ryo Takahashi, Jiro Nakane, Masaki Takeda, Chikashi Narita, Chihiro Kazuma, Satoshi Okura, Hiroko Takahashi, Hiroyuki Wada, Takeshi Tahara, Shu Matsuoka, Ayaka Masaki, Todani Shiraishi, Atsushi Shimoyama, Keiichiro Yokokawa, Yuta Nakamura, Rintaro Sageshima, Hisako Yanagida, Yuichiro Takahashi, Kunihiko Otomo, Yasuhiro Trials Study Protocol BACKGROUND: Hemodynamic stabilization is a core component in the resuscitation of septic shock. However, the optimal target blood pressure remains debatable. Previous randomized controlled trials suggested that uniformly adopting a target mean arterial pressure (MAP) higher than 65 mmHg for all adult septic shock patients would not be beneficial; however, it has also been proposed that higher target MAP may be beneficial for elderly patients, especially those with arteriosclerosis. METHODS: A multicenter, pragmatic single-blind randomized controlled trial will be conducted to compare target MAP of 80–85 mmHg (high-target) and 65–70 mmHg (control) in the resuscitation of septic shock patients admitted to 28 hospitals in Japan. Patients with septic shock aged ≥65 years are randomly assigned to the high-target or control groups. The target MAP shall be maintained for 72 h after randomization or until vasopressors are no longer needed to improve patients’ condition. To minimize the adverse effects related to catecholamines, if norepinephrine dose of ≥ 0.1 μg/kg/min is needed to maintain the target MAP, vasopressin will be initiated. Other therapeutic approaches, including fluid administration, hydrocortisone use, and antibiotic choice, will be determined by the physician in charge based on the latest clinical guidelines. The primary outcome is all-cause mortality at 90 days after randomization. DISCUSSION: The result of this trial will provide great insight on the resuscitation strategy for septic shock in the era of global aged society. Also, it will provide the better understanding on the importance of individualized treatment strategy in hemodynamic management in critically ill patients. TRIAL REGISTRATION: UMIN Clinical Trials Registry; UMIN000041775. Registered 13 September 2020. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06732-9. BioMed Central 2022-09-24 /pmc/articles/PMC9509562/ /pubmed/36153530 http://dx.doi.org/10.1186/s13063-022-06732-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Endo, Akira
Yamakawa, Kazuma
Tagami, Takashi
Umemura, Yutaka
Takahashi, Kyosuke
Nagasawa, Hiroki
Araki, Yuichi
Kojima, Mitsuaki
Sera, Toshiki
Yagi, Masayuki
Yamamoto, Ryo
Takahashi, Jiro
Nakane, Masaki
Takeda, Chikashi
Narita, Chihiro
Kazuma, Satoshi
Okura, Hiroko
Takahashi, Hiroyuki
Wada, Takeshi
Tahara, Shu
Matsuoka, Ayaka
Masaki, Todani
Shiraishi, Atsushi
Shimoyama, Keiichiro
Yokokawa, Yuta
Nakamura, Rintaro
Sageshima, Hisako
Yanagida, Yuichiro
Takahashi, Kunihiko
Otomo, Yasuhiro
Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
title Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
title_full Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
title_fullStr Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
title_full_unstemmed Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
title_short Optimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial
title_sort optimal target blood pressure in elderly with septic shock (optpress) trial: study protocol for a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509562/
https://www.ncbi.nlm.nih.gov/pubmed/36153530
http://dx.doi.org/10.1186/s13063-022-06732-9
work_keys_str_mv AT endoakira optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT yamakawakazuma optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT tagamitakashi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT umemurayutaka optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT takahashikyosuke optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT nagasawahiroki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT arakiyuichi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT kojimamitsuaki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT seratoshiki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT yagimasayuki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT yamamotoryo optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT takahashijiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT nakanemasaki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT takedachikashi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT naritachihiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT kazumasatoshi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT okurahiroko optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT takahashihiroyuki optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT wadatakeshi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT taharashu optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT matsuokaayaka optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT masakitodani optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT shiraishiatsushi optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT shimoyamakeiichiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT yokokawayuta optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT nakamurarintaro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT sageshimahisako optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT yanagidayuichiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT takahashikunihiko optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial
AT otomoyasuhiro optimaltargetbloodpressureinelderlywithsepticshockoptpresstrialstudyprotocolforarandomizedcontrolledtrial